ALLMedicine™ Plaque Psoriasis Center
Research & Reviews 2,342 results
https://www.mdedge.com/rheumatology/article/260916/psoriatic-arthritis/commentary-early-diagnosis-psa-february-2023
Vinod Chandran, MBBS, MD, DM, PhD
Jan 30th, 2023 - Vinod Chandran, MBBS, MD, DM, PhD Most patients develop psoriatic arthritis (PsA) after the onset of cutaneous psoriasis. The path toward long-term remission of PsA may be by early diagnosis and effective treatment prior to the onset of joint dama.
https://www.mdedge.com/rheumatology/article/260899/psoriatic-arthritis/fluorescence-optical-imaging-may-detect-preclinical
Heidi Splete
Jan 27th, 2023 - Fluorescence-optical imaging (FOI) identified early signs of psoriatic arthritis, based on data from 2 years of follow-up of a cohort of 389 adults at 14 rheumatology centers. Approximately 25% of individuals with psoriasis go on to develop psoria.
https://clinicaltrials.gov/ct2/show/NCT05701995
Jan 27th, 2023 - The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
https://doi.org/10.1093/bjd/ljac142
The British Journal of Dermatology; Grolleau C, Le Cleach L et. al.
Jan 27th, 2023 - Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs.|2023|Grolleau C,Le Cleach L,Shourick J,Sbidian E,Afach S,|
https://www.mdedge.com/rheumatology/article/260848/psoriatic-arthritis/fluorescence-optical-imaging-detects-early
Jan 26th, 2023 - Key clinical point: Fluorescence-optical imaging (FOI) successfully detected the early signs of musculoskeletal inflammation in hands and predicted transition from psoriasis to psoriatic arthritis (PsA) at initial stages in patients with psoriasis.
Guidelines 2 results
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/
Arcutis Biotherapeutics, Inc.
Jul 29th, 2022 - WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that t...
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.
Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...
Drugs 147 results see all →
Clinicaltrials.gov 672 results
https://clinicaltrials.gov/ct2/show/NCT05701995
Jan 27th, 2023 - The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
https://clinicaltrials.gov/ct2/show/NCT03536884
Jan 26th, 2023 - The study consists of a 48-week double-blind Treatment Period, an optional 96-week open-label extension (OLE) Period and an optional 48-week OLE2 Period for eligible subjects in the USA and Canada.
https://clinicaltrials.gov/ct2/show/NCT03598790
Jan 26th, 2023 - The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.
https://clinicaltrials.gov/ct2/show/NCT04862286
Jan 26th, 2023 - Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric parti...
https://clinicaltrials.gov/ct2/show/NCT05155098
Jan 26th, 2023 - After the baseline visit, data will be collected for each patient prospectively every 6 months for up to 2 years. At each visit, effectiveness parameters, as well as the patients' QoL and treatment pattern will be documented.
News 762 results
https://www.mdedge.com/rheumatology/article/260916/psoriatic-arthritis/commentary-early-diagnosis-psa-february-2023
Vinod Chandran, MBBS, MD, DM, PhD
Jan 30th, 2023 - Vinod Chandran, MBBS, MD, DM, PhD Most patients develop psoriatic arthritis (PsA) after the onset of cutaneous psoriasis. The path toward long-term remission of PsA may be by early diagnosis and effective treatment prior to the onset of joint dama.
https://www.mdedge.com/rheumatology/article/260899/psoriatic-arthritis/fluorescence-optical-imaging-may-detect-preclinical
Heidi Splete
Jan 27th, 2023 - Fluorescence-optical imaging (FOI) identified early signs of psoriatic arthritis, based on data from 2 years of follow-up of a cohort of 389 adults at 14 rheumatology centers. Approximately 25% of individuals with psoriasis go on to develop psoria.
https://www.mdedge.com/rheumatology/article/260848/psoriatic-arthritis/fluorescence-optical-imaging-detects-early
Jan 26th, 2023 - Key clinical point: Fluorescence-optical imaging (FOI) successfully detected the early signs of musculoskeletal inflammation in hands and predicted transition from psoriasis to psoriatic arthritis (PsA) at initial stages in patients with psoriasis.
https://www.reuters.com/article/abbvie-outlook/abbvie-expects-sales-of-two-drugs-to-exceed-21-bln-in-2027-idUSL4N33V2OW
Jan 10th, 2023 - Jan 10 (Reuters) - AbbVie said on Tuesday it expects combined peak sales of plaque psoriasis drug Skyrizi and anti-inflammatory medicine Rinvoq to exceed $21 billion in 2027. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
https://www.mdedge.com/dermatology/article/260398/psoriasis
Heidi Splete
Dec 29th, 2022 - LAS VEGAS – Although the range of oral psoriasis therapies continues to expand, “topical therapy is still the cornerstone of the treatment of psoriasis,” said Linda Stein Gold, MD, in a presentation at Medscape Live’s annual Las Vegas Dermatology.
